Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - MainLine Health
mi
from
Wynnewood, PA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - MainLine Health
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Lankenau Cancer Center at Lankenau Hospital
mi
from
Wynnewood, PA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Lankenau Cancer Center at Lankenau Hospital
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Avera Cancer Institute
mi
from
Sioux Falls, SD
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Harrington Cancer Center
mi
from
Amarillo, TX
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Harrington Cancer Center
mi
from
Amarillo, TX
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic - Indianhead Center
mi
from
Rice Lake, WI
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic - Indianhead Center
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Click here to add this to my saved trials
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer
Improving Employment Among Gynecologic Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer
Improving Employment Among Gynecologic Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer
Restorative Yoga for Women With Ovarian Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer
Restorative Yoga for Women With Ovarian Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
Status: Enrolling
Updated:  12/31/1969
Maimonides Medical Center, OBGYN clinic
mi
from
Brooklyn, NY
Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
Status: Enrolling
Updated: 12/31/1969
Maimonides Medical Center, OBGYN clinic
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Heat Therapy and Cardiometabolic Health in Obese Women
Heat Therapy and Cardiometabolic Health in Obese Women
Status: Enrolling
Updated:  12/31/1969
University of Oregon
mi
from
Eugene, OR
Heat Therapy and Cardiometabolic Health in Obese Women
Heat Therapy and Cardiometabolic Health in Obese Women
Status: Enrolling
Updated: 12/31/1969
University of Oregon
mi
from
Eugene, OR
Click here to add this to my saved trials
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital
mi
from
Aurora, CO
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Northeast Georgia Medical Center-Gainesville
mi
from
Gainesville, GA
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Northeast Georgia Medical Center-Gainesville
mi
from
Gainesville, GA
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Hinsdale Hematology Oncology Associates Incorporated
mi
from
Hinsdale, IL
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Hinsdale Hematology Oncology Associates Incorporated
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Memorial Health Care
mi
from
Worcester, MA
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Memorial Health Care
mi
from
Worcester, MA
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Univ of Massachusetts Med School
mi
from
Worcester, MA
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Nebraska Methodist Hospital
mi
from
Omaha, NE
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
MetroHealth Med Ctr
mi
from
Cleveland, OH
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Riverside Methodist Hospital
mi
from
Columbus, OH
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital
mi
from
Dayton, OH
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated:  12/31/1969
Abington Memorial Hospital
mi
from
Abington, PA
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Status: Enrolling
Updated: 12/31/1969
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials